Abstract
Background
PET–CT is important for evaluating the cancer stage preoperatively. In patients with locally advanced disease, who are candidates for curative treatment modalities following computed tomography (CT) and ultrasonography evaluation, PET–CT can show distant metastases and spare patients unnecessary surgical interventions. We aimed to evaluate the contribution of PET–CT scans compared to conventional imaging studies on the change of treatment plan in patients with locally advanced esophagogastric cancer from neoadjuvant to palliative setting.
Materials and methods
In this study, 91 patients with histopathologically proven diagnosis of esophageal or gastric cancer in our clinic between the years 2010–2014 were included. Prior to PET–CT evaluation, all of the patients were evaluated with thorax and abdomen computed tomography. Seventy-six of these patients were further evaluated by PET–CT due to ambiguous findings on computed tomography and 15 of them for staging purposes. The patients, who were shown to have distant metastases on conventional radiological imaging, were excluded from the study population.
Results
Ninety-one patients were included in the study. Their median age was 57 (range 30–80) years and three-quarters of the patients were male. Most of the patients were evaluated by PET–CT due to suspicion of distant metastasis (83.5 %). Primary sites of the tumors on PET–CT were: esophagus 38.5 % and stomach 61.5 %. Between CT and PET–CT tumor stage and pathological lymphadenopathy concordance rates were 75.8, and 69.2 %, respectively. On PET–CT evaluation 47.3 % of patients had distant metastasis. New metastases were detected in 34.1 % of patients by PET–CT despite entering to scanning field of tomography. Following the PET–CT evaluation due to detected metastasis, 47.3 % of patients’ treatment plan was changed from neoadjuvant to palliative therapy.
Conclusion
In the current study, 47.3 % (n = 43) of patients had distant metastasis that were not detected by CT evaluation. These patients were spared unnecessary surgical interventions. Evaluating the locally advanced gastric and esophageal cancer patients for PET–CT new metastasis could be indicated when the treatment plan of these patients would be changed from curative to palliative.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wu CX, Zhu ZH. Diagnosis and evaluation of gastric cancer by positron emission tomography. World J Gastroenterol. 2014;20:4574–85.
Bollschweiler E, Berlth F, Baltin C, Stefan M, Arnulf H. Treatment of early gastric cancer in the Western World. World J Gastroenterol. 2014;20:5672–8.
Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis. 2014;6(Suppl 3):S289–97.
Orditura M, Galizia G, Sforza V, Alessio F, Maria M, Francesca A, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20:1635–49.
Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6:112–20.
Ho MY, Al-Barrak J, Peixoto RD, Cheung WY. The association between county-level surgeon density and esophageal and gastric cancer mortality. J Gastrointest Cancer. 2014;45:487–93.
Molina R, Lamarca A, Martinez-Amores B, Gutiérrez A, Blázquez A, López A, et al. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience. Eur J Surg Oncol. 2013;39:814–22.
Yoon H, Lee DH. New approaches to gastric cancer staging: beyond endoscopic ultrasound, computed tomography and positron emission tomography. World J Gastroenterol. 2014;20:13783–90.
Yegin EG, Duman DG. Staging of esophageal and gastric cancer in 2014. Minerva Med. 2014;105:391–411.
Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48–63.
Al-Taan OS, Eltweri A, Sharpe D, Rodgers PM, Ubhi SS, Bowrey DJ. Prognostic value of baseline FDG uptake on PET–CT in esophageal carcinoma. World J Gastrointest Oncol. 2014;6:139–44.
Choi HS, Yoo IeR, Park HL, Choi EK, Kim SH, Lee WH. Role of 18F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients. Clin Imaging. 2014;38(2):109–14.
Guan ZW, Xu BX, Wang RM, Sun L, Tian JH. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature. Hell J Nucl Med. 2013;16(2):97–102.
Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005;103:148–56.
Ha TK, Choi YY, Song SY, Kwon SJ. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer. J Korean Surg Soc. 2011;81:104–10.
Park K, Jang G, Baek S, Song H. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori. 2014;100:201–6.
Kim SH, Won KS, Hwang I, Choi BW, Jo I, Zeon SK. Simultaneous splenic and colonic metastases from gastric cancer: different FDG avidities according to the density of cancer cells imaged on FDG PET/CT. Clin Nucl Med. 2013;38(1):60–2.
Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015;56(4):523–9.
Coupe NA, Karikios D, Chong S, Yap J, Ng W, Merrett N, et al. Metabolic information on staging FDG-PET–CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Ann Nucl Med. 2014;28:128–35.
Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol. 2010;136:1929–35.
Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999;68:1133–6 (discussion 1136–7).
Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–10.
Blencowe NS, Whistance RN, Strong S, Hotton EJ, Ganesh S, Roach H, et al. Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer. Br J Cancer. 2013;109:1445–50.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hocazade, C., Özdemir, N., Yazici, O. et al. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer. Ann Nucl Med 29, 621–626 (2015). https://doi.org/10.1007/s12149-015-0985-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-015-0985-3